Mylan Symbicort Trial Looms As Company Eyes First US Generic
Teva Has Previously Settled ANDA Litigation
A trial will begin next month in Mylan’s bid to overcome patents shielding AstraZeneca’s Symbicort respiratory brand in the US. With rival Teva having previously settled ANDA action, Mylan is in the driving seat for a first substitutable generic.
